 | |||||
| cannabidiol for epilepsy | |||||
| NEWS | |||||
| Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in ... - BioSpace Meaningful 50% responder rates in subgroups of highly refractory seizure patients on concomitant medications cannabidiol (n=12) or everolimus ...
| |||||
| See more results | Edit this alert | |||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
